Dr Reddy's Labs recalls over 3 lakh bottles of Cinacalcet tablets in US over manufacturing issues
Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of Cinacalcet tablets, a medication used for treatment of high calcium levels in the blood and hyperparathyroidism, in the
Dr Reddy's recalls over 3.3 lakh bottles of generic medication in US: USFDA
Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of Cinacalcet tablets in the US due to manufacturing issues. The recall is due to the presence of an impurity above FDA limits. The recall affects 30 mg,
Dr Reddy's recalls over 3.3 lakh bottles of medication due to manufacturing issues
Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of a medication used to treat high calcium levels in the blood and hyperparathyroidism in the US market due to manufacturing issues.
Dr. Reddy's Labs Recalls 3.3 Lakh Bottles Of Medication In US Due To Manufacturing Issues
The recall is due to the 'presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit', it added.
Dr Reddy’s recalls over 3 lakh bottles of Cinacalcet tablets in US due to manufacturing issues
According to the latest Enforcement Report by the US Food and Drug Administration, Dr Reddy's is recalling the 3,31,590 bottles of Cinacalcet tablets in multiple strengths in the American market due to CGMP (current good manufacturing practice) deviations.
Dr Reddy’s Laboratories recalls over 3.31 lakh bottles of Cinacalcet tablets
Dr Reddy’s Laboratories has announced a recall of more than 3.31 lakh bottles of Cinacalcet tablets sold in the US. These tablets are used to treat high calcium levels and hyperparathyroidism.The recall is due to manufacturing problems that violate current good manufacturing practices (CGMP).
FiercePharma1d
Dr. Reddy's pulls more than 300K bottles of thyroid drug, citing presence of a carcinogen
The U.S. unit of Indian drugmaker Dr. Reddy’s Laboratories is recalling 331,590 bottles of cinacalcet tablets used to treat hyperparathyroidism due to the presence of a known carcinogen. | The U.S.
Dr Reddy’s Laboratories Q2 Results: Net profit drops 9.5% to ₹1,342 crore on acquisition cost, revenue up 16.5% YoY
The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.
Nature11mon
Should cinacalcet be used in patients who are not on dialysis?
Cinacalcet is an effective treatment for secondary hyperparathyroidism in patients on dialysis. Until now, no randomized, placebo-controlled, long-term trial has tested this drug in individuals ...
money.rediff3d
Dr Reddy's Recalls Cinacalcet Tablets in US: USFDA
Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of Cinacalcet tablets in the US due to manufacturing issues. The ...
Medscape2d
Drug Insight: Renal Indications of Calcimimetics
Cinacalcet (Sensipar ® /Mimpara ®, Amgen Inc., Thousand Oaks, CA), the first-in-class calcimimetic agent approved for treatment of secondary hyperparathyroidism in dialysis patients, is ...
Nature2mon
Cinacalcet—can it control hypercalcemia?
During the initial titration phase of up to 16 weeks, patients received increasing dosages of cinacalcet until the serum calcium concentration was <2.5 mmol/l, the highest possible dosage was ...
Stocks to Watch, Nov 4: Sun Pharma, Dr Reddy's, Zen Tech, Afcons Infra
Stocks to watch on Monday, November 4, 2024: Indian bourses are preparing for a negative start on Monday, indicated GIFT ...